We are live on ! Find out more
BRNS

Barinthus Biotherapeutics
BRNS

Delisted

BRNS was delisted on the 8th of September, 2026.

Back to rankings

14 hedge funds and large institutions have $7.89M invested in Barinthus Biotherapeutics in 2026 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 3 increasing their positions, 1 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 1

100% more first-time investments, than exits

New positions opened: 2 | Existing positions closed: 1

8% more funds holding

Funds holding: 13 → 14 (+1)

3.41% more ownership

Funds ownership: 19.35% → 22.76% (+3.4%)

50% less funds holding in top 10

Funds holding in top 10: 2 → 1 (-1)

84% less capital invested

Capital invested by funds: $48.3M → $7.89M (-$40.4M)

Holders
14
Holders Change
+1
Holders Change %
+7.69%
% of All Funds
0.17%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.01%
New
2
Increased
3
Reduced
1
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
RC
Rangeley Capital
Connecticut
+$49.4K
2
GS
GTS Securities
Florida
+$48.2K
3
Renaissance Technologies
Renaissance Technologies
New York
+$5.21K
4
Citadel Advisors
Citadel Advisors
Florida
+$130

Top Sellers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
-$2.21K
2
Morgan Stanley
Morgan Stanley
New York
-$788

BRNS Hedge Fund Activity: Q1 2026 in Review

14 of the 8,196 institutional investors tracked by Wall St. Rank reported a position in Barinthus Biotherapeutics (BRNS) for Q1 2026, worth a combined $7.89M — down 84% from $48.3M a quarter earlier.

Buyers outnumbered sellers: 2 funds opened new BRNS positions and 1 closed out — a net gain of 1 holder — while 3 added to existing stakes and 1 trimmed.

The largest buyer was Rangeley Capital, adding an estimated $49.4K. The largest seller was UBS Group, exiting entirely with an estimated $2.21K sold.

  • 14 institutional investors held Barinthus Biotherapeutics (BRNS) as of Q1 2026, up from 13 in Q4 2025.
  • Funds reported $7.89M of Barinthus Biotherapeutics stock for Q1 2026, down 84% quarter-over-quarter.
  • 2 funds opened new Barinthus Biotherapeutics positions in Q1 2026 and 1 closed out, a net change of +1 holder.
  • The largest Barinthus Biotherapeutics buyer in Q1 2026 was Rangeley Capital, an estimated $49.4K added.
  • The largest Barinthus Biotherapeutics seller in Q1 2026 was UBS Group, an estimated $2.21K sold.

Based on aggregated 13F filings for Q1 2026.